Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Ascletis Starts China Bridging Trial of FXR Agonist for Hepatitis B

publication date: Jul 14, 2021

Ascletis Pharma of Hangzhou started a China bridging trial of its FXR agonist following a successful US Phase I trial of ASC42 in healthy patients. The China trial will also enroll healthy patients in a placebo-controlled, dose escalation trial. As an FXR agonist, ASC42 inhibits the transcription of chronic hepatitis B virus. In preclinical tests, the candidate showed promise as a cure for CHB. Ascletis developed ASC42 in-house and believes it has best-in-class potential. It is also being tested as a treatment for NASH. More details....

Stock Symbol: (HK: 1672)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.